Icahn School of Medicine
Scores focused on the biochemical pathways associated with disease and pairing these scores with other risk assessments could improve predictive value, the data showed.
Prostate Cancer Polygenic Score Does Not Improve High-Grade Disease Prediction Over Clinical Factors
Researchers found that adding genetic risk score data did not improve their ability to predict aggressive prostate cancer cases over conventional risk stratification approaches.
BioMark Diagnostics, Icahn Mount Sinai to Develop Multiomic Lung Cancer Tests
The partners also aim to develop a test for determining lung cancer subtype and stage using circulating tumor cells and metabolomics.
Multiple Myeloma Patient Similarity Network Reveals Prognostically Informative Subgroups
Researchers identified 12 multiple myeloma subgroups based on mutation, copy number, chromosomal rearrangement, and expression features in more than 650 tumors.
Cancer Genomic Analysis Reveals Distinct Features in Tumors From Patients Under 50 Years Old
Researchers saw distinct driver mutation, tumor microenvironment features, and more when they compared tumors from dozens of cancer types in patients younger or older than 50.